MELINDA BECKNELL: Open Payments
NPI 1841999786 · KENNETT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 51 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $375 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $205 |
| Otsuka America Pharmaceutical, Inc. | 13 | $183 |
| Neurocrine BioSciences, Inc. | 10 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Alkermes, Inc. | 4 | $87 |
| Janssen Pharmaceuticals, Inc | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| ABBVIE INC. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Lundbeck LLC | 1 | $17 |
Products named: UZEDY, INGREZZA, REXULTI, CAPLYTA, ARISTADA, INVEGA SUSTENNA, ABILIFY MAINTENA, FANAPT.
Industry payments across MO — which companies pay providers there.
